G2100: In Vitro Chemoresistance and Chemosensitivity Assays
This policy defines Blue Cross and Blue Shield of Louisiana's coverage stance and limitations for in vitro chemotherapy sensitivity and resistance assays (proprietary and non-proprietary), lists applicable CPT/HCPCS codes, summarizes evidence and guideline positions, and records revision history and regulatory applicability.
02/01/2026 - Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references; literature review did not necessitate modifications to coverage criteria.
01/01/2025 - Reviewed and Updated: Updated background, guidelines and references; added CPT code 0525U.
10/01/2024 - Off-Cycle Coding Modification: Updated test descriptor for CPT code 0248U.
07/01/2024 - Client Requested Variance: Removal of code 0285U.
05/01/2024 - Reviewed and Updated: Edits for clarity; literature review did not necessitate modifications to coverage criteria.
01/01/2024 - Off-Cycle Coding Modification: Added CPT code 0435U.
04/01/2023 - Off-Cycle Coding Modification: Removed deleted PLA codes 0324U, 0325U.
03/10/2023 - Added CPT codes 0249U, 0285U, 0324U, and 0325U.
05/15/2022 - Initial Policy Implementation
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.